The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2022 | Challenges associated with implementing immune checkpoint blockade in SCLC
Giuseppe Lamberti, MD, University Hospital of Bologna, Bologna, Italy, talks on challenges associated with implementing immune checkpoint inhibitors in small cell lung cancer (SCLC) Current data suggests that immune checkpoint inhibitors are benefitting a subgroup of patients with SCLC. However, the main challenge is deciphering which subgroup of patients are benefitting, which has yet to be elucidated due to the current lack of biomarkers. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.
![Impact of [18F]FDG PET/CT-derived metabolic parameters on outcomes in extensive-stage SCLC](https://i.ytimg.com/vi/soBIdqv8jvQ/mqdefault.jpg)
